Compounds > capecitabine
Page last updated: 2024-08-24

capecitabine and Pituitary Neoplasms

capecitabine has been researched along with Pituitary Neoplasms in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (33.33)24.3611
2020's4 (66.67)2.80

Authors

AuthorsStudies
Fukuoka, H; Inoshita, N; Ishida, A; Ogawa, W; Shichi, H; Yamada, S1
Aubanell, A; Biagetti, B; Capdevila, J; Chaachou, A; Filippi-Arriaga, F; Garcia-Alvarez, A; Hernandez Hernandez, I; Hernando, J; Martínez-Saez, E; Mirallas, O1
Chik, CL; Easaw, J; Inoshita, N; Mehta, V; Nakano-Tateno, T; Satou, M; Tateno, T; van Landeghem, FKH1
Araki, T; Kawakami, Y; Lau, KJ; McMahon, C; Nakano-Tateno, T; Tateno, T; Wang, J1
Burman, P; Dekkers, OM; McCormack, A; Petersenn, S; Popovic, V; Raverot, G; Trouillas, J1
Arnal, AV; Donovan, LE; Odia, Y; Wang, SH1

Reviews

1 review(s) available for capecitabine and Pituitary Neoplasms

ArticleYear
Multimodal Non-Surgical Treatments of Aggressive Pituitary Tumors.
    Frontiers in endocrinology, 2021, Volume: 12

    Topics: Antineoplastic Agents; Capecitabine; Combined Modality Therapy; Dopamine Agonists; Humans; Pituitary Neoplasms; Temozolomide; Treatment Outcome

2021

Other Studies

5 other study(ies) available for capecitabine and Pituitary Neoplasms

ArticleYear
Efficacy of temozolomide combined with capecitabine (CAPTEM) on refractory prolactinomas as assessed using an ex vivo 3D spheroid assay.
    Pituitary, 2022, Volume: 25, Issue:2

    Topics: Capecitabine; Dopamine Agonists; Humans; Pituitary Neoplasms; Prolactinoma; Temozolomide

2022
Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson's Syndrome: A Case Report.
    Frontiers in endocrinology, 2021, Volume: 12

    Topics: Adenoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Humans; Male; Middle Aged; Nelson Syndrome; Neoplasm Invasiveness; Pituitary Neoplasms; Spain; Temozolomide; Treatment Outcome; Tumor Burden

2021
Effects of CAPTEM (Capecitabine and Temozolomide) on a Corticotroph Carcinoma and an Aggressive Corticotroph Tumor.
    Endocrine pathology, 2021, Volume: 32, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Neuroendocrine; Corticotrophs; Humans; Male; Middle Aged; Pituitary Neoplasms; Temozolomide

2021
Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016.
    European journal of endocrinology, 2018, Volume: 178, Issue:3

    Topics: Adenoma; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoma; Carmustine; Child; Child, Preschool; Cranial Irradiation; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Endocrinology; Europe; Female; Humans; Ki-67 Antigen; Male; Middle Aged; Neoplasm Invasiveness; Neurosurgical Procedures; Pituitary Neoplasms; Societies, Medical; Surveys and Questionnaires; Temozolomide; Thalidomide; Tumor Suppressor Proteins; Young Adult

2018
Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy.
    CNS oncology, 2016, Volume: 5, Issue:4

    Topics: Adenoma; Adrenocorticotropic Hormone; AMP-Activated Protein Kinase Kinases; Antineoplastic Agents; Brain; Brain Neoplasms; Capecitabine; Dacarbazine; Everolimus; Female; Humans; Ki-67 Antigen; Magnetic Resonance Imaging; Middle Aged; Mutation; Pituitary Neoplasms; Protein Serine-Threonine Kinases; Temozolomide

2016